OP-1250: A potent orally available complete antagonist of estrogen receptor-mediated signaling that shrinks wild type and mutant breast tumors. (October 2020) - Hodges-Gallagher, L.; Sun, R.; Myles, D.; Klein, P.; Zujewski, J.A.; Harmon, C.; Kushner, P.